Proteflazid®: outcome analysis of clinical trials studying the impact of human herpesvirus infection on some cellular immunity indicators and gestation course in women.
An outcome analysis of the clinical trials evaluating the clinical and immunological efficacy of the drug Proteflazid® in the treatment of diseases associated with herpesvirus infection in pregnant women is presented. Objective of the study was to evaluate the effects of Proteflazid® on the cellular component of the immune system and gestation course in women with HHV infection by using meta-analysis and statistical analysis (based on Student's t-test) of the clinical findings. The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 234 pregnant women during the period from 2003 to 2012. The obtained data prove the efficacy of the preparation Proteflazid ® in treating pregnant women with HHV infection. Administration of the drug Proteflazid® in the treatment of herpesvirus infection in pregnant women contributes to the cellular immunity normalization, which in turn has a positive effect on the course and outcome of pregnancy. Therapy with the drug Proteflazid® is etiologically and pathogenetically substantiated, contributes to the normalization of cellular immunity parameters, which, in turn, has a positive effect on the course and outcome of pregnancy.